EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PAK6 rescues pathogenic LRRK2-mediated ciliogenesis and centrosomal cohesion defects in a mutation-specific manner

Lucia Iannotta iD, Rachel Fasiczka, Giulia Favetta iD, Yibo Zhao, Elena Giusto, Elena Dall'Ara, Jianning Wei, Franz Y Ho, Claudia Ciriani, Susanna Cogo, Isabella Tessari, Ciro Iaccarino und 9 weitere

Cell Death & Disease · 2024

DOI: 10.1038/s41419-024-07124-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Death & Disease, 2024. Verfasst von Lucia Iannotta und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, University of Padova, Padova, PD, Italy. Hauptthemen laut MEDLINE: Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, p21-Activated Kinases, Centrosome, Cilia. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Div…, Florida Department of Health, Michael J. Fox Foundation for Parkinson's Research (Michael J. Fox Foundation).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

P21 activated kinase 6 (PAK6) is a serine-threonine kinase with physiological expression enriched in the brain and overexpressed in a number of human tumors. While the role of PAK6 in cancer cells has been extensively investigated, the physiological function of the kinase in the context of brain cells is poorly understood. Our previous work uncovered a link between PAK6 and the Parkinson’s disease (PD)-associated kinase LRRK2, with PAK6 controlling LRRK2 activity and subcellular localization via phosphorylation of 14–3–3 proteins. Here, to gain more insights into PAK6 physiological function, we performed protein-protein interaction arrays and identified a subgroup of PAK6 binders related to ciliogenesis. We confirmed that endogenous PAK6 localizes at both the centrosome and the cilium, and positively regulates ciliogenesis not only in tumor cells but also in neurons and astrocytes. Notably, PAK6 rescues ciliogenesis and centrosomal cohesion defects associated with the G2019S but not the R1441C LRRK2 PD mutation. Since PAK6 binds LRRK2 via its GTPase/Roc-COR domain and the R1441C mutation is located in the Roc domain, we used microscale thermophoresis and AlphaFold2-based computational analysis to demonstrate that PD mutations in LRRK2 affecting the Roc-COR structure substantially decrease PAK6 affinity, providing a rationale for the differential protective effect of PAK6 toward the distinct forms of mutant LRRK2. Altogether, our study discloses a novel role of PAK6 in ciliogenesis and points to PAK6 as the first LRRK2 modifier with PD mutation-specificity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2p21-Activated KinasesCentrosomeCiliaMutationHumansAnimalsParkinson DiseasePhosphorylationHEK293 CellsProtein BindingNeuronsAstrocytesMice

Substanzen

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2p21-Activated KinasesLRRK2 protein, humanPAK6 protein, human

Autor:innen und Institutionen

  • Department of Biology, University of Padova, Padova, PD, Italy.
  • National Research Council, c/o Humanitas Research Hospital, Institute of Neuroscience, Rozzano, Italy.
  • Department of Anesthesiology, Rutgers New Jersey Medical School, Newark, NJ, USA.
  • University College London, School of Pharmacy, London, UK.
  • IRCCS San Camillo Hospital, Venice, Italy.
  • Department of Cell Biochemistry, University of Groningen, Groningen, Netherlands.

ORCID-Profile: Lucia Iannotta, Giulia Favetta, Luigi Bubacco, Michael L Lu, Elisa Greggio

Förderung

  • U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Div…
  • Florida Department of Health
  • Michael J. Fox Foundation for Parkinson's Research (Michael J. Fox Foundation)
  • University of Padova BIRD funding
  • Busch Biomedical Research Grant
  • U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute

Zitieren

APA

Iannotta, L., Fasiczka, R., Favetta, G., Zhao, Y., Giusto, E., Dall'Ara, E., Wei, J., Ho, F. Y., Ciriani, C., Cogo, S., Tessari, I., Iaccarino, C., Liberelle, M., Bubacco, L., Taymans, J. M., Manzoni, C., Kortholt, A., Civiero, L., Hilfiker, S., …, & Greggio, E. (2024). PAK6 rescues pathogenic LRRK2-mediated ciliogenesis and centrosomal cohesion defects in a mutation-specific manner. Cell Death & Disease. https://doi.org/10.1038/s41419-024-07124-4

Vancouver

Iannotta L, Fasiczka R, Favetta G, Zhao Y, Giusto E, Dall'Ara E, et al. PAK6 rescues pathogenic LRRK2-mediated ciliogenesis and centrosomal cohesion defects in a mutation-specific manner. Cell Death & Disease. 2024. doi:10.1038/s41419-024-07124-4

BibTeX
@article{Iannotta2024,
  author = {Iannotta, Lucia and Fasiczka, Rachel and Favetta, Giulia and Zhao, Yibo and Giusto, Elena and Dall'Ara, Elena and Wei, Jianning and Ho, Franz Y and Ciriani, Claudia and Cogo, Susanna and Tessari, Isabella and Iaccarino, Ciro and Liberelle, Maxime and Bubacco, Luigi and Taymans, Jean-Marc and Manzoni, Claudia and Kortholt, Arjan and Civiero, Laura and Hilfiker, Sabine and Lu, Michael L and Greggio, Elisa},
  title = {PAK6 rescues pathogenic LRRK2-mediated ciliogenesis and centrosomal cohesion defects in a mutation-specific manner},
  journal = {Cell Death & Disease},
  year = {2024},
  doi = {10.1038/s41419-024-07124-4}
}
Kostenlos starten →